1. Home
  2. BAX

as of 03-09-2026 3:53pm EST

$17.91
+$0.18
+1.02%
Stocks Health Care Medical/Dental Instruments Nasdaq

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Founded: 1931 Country:
United States
United States
Employees: N/A City: DEERFIELD
Market Cap: 10.2B IPO Year: 1994
Target Price: $22.38 AVG Volume (30 days): 9.4M
Analyst Decision: Hold Number of Analysts: 9
Dividend Yield:
0.23%
Dividend Payout Frequency: quarterly
EPS: -1.87 EPS Growth: -47.24
52 Week Low/High: $17.40 - $36.57 Next Earning Date: N/A
Revenue: $11,244,000,000 Revenue Growth: 5.72%
Revenue Growth (this year): 1.9% Revenue Growth (next year): 2.09%
P/E Ratio: -9.48 Index:
Free Cash Flow: 332.0M FCF Growth: -42.06%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2025
Q4

Q4 2025 Earnings

8-K SELL

Feb 12, 2026 · 100% conf.

AI Prediction SELL

1D

-0.23%

$18.67

5D

-4.36%

$17.89

20D

-1.84%

$18.37

Price: $18.71 Prob +5D: 0% AUC: 1.000
0001628280-26-007474

bax-202602100000010456false00000104562026-02-102026-02-100000010456bax:CommonStock1.00PerValueMemberexch:XNYS2026-02-102026-02-100000010456bax:CommonStock1.00PerValueMemberexch:XCHI2026-02-102026-02-100000010456bax:GlobalNotes13Due2029Memberexch:XNYS2026-02-102026-02-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 10, 2026 Baxter International Inc. (Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

1-444836-0781620 (Commission File Number)(I.R.S. Employer Identification No.)

One Baxter Parkway, Deerfield, Illinois 60015 (Address of principal executive offices)(Zip Code)

(224)948-2000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange 1.3% Global Notes due 2029BAX 29New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter): ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐

Item 2.02 Results of Operations and Financial Condition. On February 12, 2026, Baxter International Inc. (the Company) issued an earnings press release for the period ended December 31, 2025. The press release, including attachments, is furnished as Exhibit 99.1 to this report. The information in this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events Effective February 11, 2026, the Company's Board of Directors declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on April 1, 2026, to stockholders of record as of February 27, 2026.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Michael R. McDonnell On February 10, 2026, Baxter International Inc. (the “Company”) appointed Michael R. McDonnell to its Board of Directors (the “Board”), effective February 13, 2026. Mr. McDonnell has also been appointed to serve as a member of the Audit Committee. Michael McDonnell served as the Executive Vice President and Chief Financial Officer of Biogen Inc. from August 2020 through February 2025. He also served as Executive Vice President and Chief Financial Officer of IQVIA Holdings Inc. (f/k/a Quintiles IMS) from December 2015 through July 2020. Prior to that, Mr. McDonnell served as the Executive Vice President and Chief Financial Officer of Intelsat S.A. from November 2008 to December 2015, as Executive Vice President, Chief Financial Officer of MCG Capital Corporation from September 2004 until October 2008 and also as MCG Capital Corporation’s Chief Operating Officer from August 2006 until October 2008. Before joining MCG Capital Corporation, Mr. McDonnell served as Executive Vice President and Chief Financial Officer for Echo Star Communications Corporation (d/b/a DISH Network Corporation) from July 2004 until August 2004 and as its Senior Vice President and Chief Financial Officer from August 2000 to July 2004. Mr. McDonnell spent 14 years at PricewaterhouseCoopers LLP, including four years as a partner. Mr. McDonnell also serves on the board of directors of Merit Medical Systems, Inc. Mr. McDonnell will be compensated f

2025
Q3

Q3 2025 Earnings

8-K

Oct 30, 2025

0001628280-25-047311

bax-202510300000010456false00000104562025-10-302025-10-300000010456bax:CommonStock1.00PerValueMemberexch:XCHI2025-10-302025-10-300000010456bax:CommonStock1.00PerValueMemberexch:XNYS2025-10-302025-10-300000010456bax:GlobalNotes13Due2029Memberexch:XNYS2025-10-302025-10-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 30, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

1-444836-0781620 (Commission File Number)(I.R.S. Employer Identification No.)

One Baxter Parkway, Deerfield, Illinois 60015 (Address of principal executive offices)(Zip Code)

(224)948-2000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange 1.3% Global Notes due 2029BAX 29New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter): ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act:   ☐

Item 2.02 Results of Operations and Financial Condition. On October 30, 2025, Baxter International Inc. (the Company) issued an earnings press release for the period ended September 30, 2025. The press release, including attachments, is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits. (d)Exhibits.

Exhibit NumberDescription

99.1Press Release Dated October 30, 2025

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2025

BAXTER INTERNATIONAL INC.

By:/s/ Joel T. Grade Name:Joel T. Grade Title:Executive Vice President and Chief Financial Officer

2025
Q2

Q2 2025 Earnings

8-K

Jul 31, 2025

0001628280-25-036835

bax-202507310000010456false00000104562025-07-312025-07-310000010456exch:XCHIbax:CommonStock1.00PerValueMember2025-07-312025-07-310000010456exch:XNYSbax:CommonStock1.00PerValueMember2025-07-312025-07-310000010456exch:XNYSbax:GlobalNotes13Due2029Member2025-07-312025-07-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 31, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

1-444836-0781620 (Commission File Number)(I.R.S. Employer Identification No.)

One Baxter Parkway, Deerfield, Illinois 60015 (Address of principal executive offices)(Zip Code)

(224)948-2000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange 1.3% Global Notes due 2029BAX 29New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter): ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act:   ☐

Item 2.02 Results of Operations and Financial Condition. On July 31, 2025, Baxter International Inc. (the Company) issued an earnings press release for the period ended June 30, 2025. The press release, including attachments, is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits. (d)Exhibits.

Exhibit NumberDescription

99.1Press Release Dated July 31, 2025

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 31, 2025

BAXTER INTERNATIONAL INC.

By:/s/ Joel T. Grade Name:Joel T. Grade Title:Executive Vice President and Chief Financial Officer

Latest Baxter International Inc. News

BAX Breaking Stock News: Dive into BAX Ticker-Specific Updates for Smart Investing

All BAX News

Share on Social Networks: